BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29733904)

  • 1. C1QTNF1 attenuates angiotensin II-induced cardiac hypertrophy via activation of the AMPKa pathway.
    Wu L; Gao L; Zhang D; Yao R; Huang Z; Du B; Wang Z; Xiao L; Li P; Li Y; Liang C; Zhang Y
    Free Radic Biol Med; 2018 Jun; 121():215-230. PubMed ID: 29733904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.
    Tang X; Chen XF; Wang NY; Wang XM; Liang ST; Zheng W; Lu YB; Zhao X; Hao DL; Zhang ZQ; Zou MH; Liu DP; Chen HZ
    Circulation; 2017 Nov; 136(21):2051-2067. PubMed ID: 28947430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic blockade of class I PI3-kinase attenuates Ang II-induced cardiac hypertrophy and autophagic alteration.
    Yan W; Guo LR; Zhang Q; Sun WZ; O'Rourke ST; Liu KX; Sun CW
    Eur Rev Med Pharmacol Sci; 2015; 19(5):772-83. PubMed ID: 25807429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.
    Wu MP; Zhang YS; Xu X; Zhou Q; Li JD; Yan C
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):157-166. PubMed ID: 28321644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1.
    Li S; Zhu Z; Xue M; Yi X; Liang J; Niu C; Chen G; Shen Y; Zhang H; Zheng J; Zhao C; Liang Y; Cong W; Wang Y; Jin L
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1241-1252. PubMed ID: 30677512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alamandine acts via MrgD to induce AMPK/NO activation against ANG II hypertrophy in cardiomyocytes.
    Jesus ICG; Scalzo S; Alves F; Marques K; Rocha-Resende C; Bader M; Santos RAS; Guatimosim S
    Am J Physiol Cell Physiol; 2018 Jun; 314(6):C702-C711. PubMed ID: 29443552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
    Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY
    Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaempferol Alleviates Angiotensin II-Induced Cardiac Dysfunction and Interstitial Fibrosis in Mice.
    Liu Y; Gao L; Guo S; Liu Y; Zhao X; Li R; Yan X; Li Y; Wang S; Niu X; Yao L; Zhang Y; Li L; Yang H
    Cell Physiol Biochem; 2017; 43(6):2253-2263. PubMed ID: 29073623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocyte-specific enhancer factor 2C: a novel target gene of miR-214-3p in suppressing angiotensin II-induced cardiomyocyte hypertrophy.
    Tang CM; Liu FZ; Zhu JN; Fu YH; Lin QX; Deng CY; Hu ZQ; Yang H; Zheng XL; Cheng JD; Wu SL; Shan ZX
    Sci Rep; 2016 Oct; 6():36146. PubMed ID: 27796324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin alleviates angiotensin-II-induced cardiac hypertrophy via activating MICU1 pathway.
    Yang Y; Du J; Xu R; Shen Y; Yang D; Li D; Hu H; Pei H; Yang Y
    Aging (Albany NY); 2020 Nov; 13(1):493-515. PubMed ID: 33259334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crucial Role of ROCK2-Mediated Phosphorylation and Upregulation of FHOD3 in the Pathogenesis of Angiotensin II-Induced Cardiac Hypertrophy.
    Zhou Q; Wei SS; Wang H; Wang Q; Li W; Li G; Hou JW; Chen XM; Chen J; Xu WP; Li YG; Wang YP
    Hypertension; 2017 Jun; 69(6):1070-1083. PubMed ID: 28438902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy.
    Sun B; Huo R; Sheng Y; Li Y; Xie X; Chen C; Liu HB; Li N; Li CB; Guo WT; Zhu JX; Yang BF; Dong DL
    Hypertension; 2013 Feb; 61(2):352-60. PubMed ID: 23248151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophilin A promotes cardiac hypertrophy in apolipoprotein E-deficient mice.
    Satoh K; Nigro P; Zeidan A; Soe NN; Jaffré F; Oikawa M; O'Dell MR; Cui Z; Menon P; Lu Y; Mohan A; Yan C; Blaxall BC; Berk BC
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1116-23. PubMed ID: 21330604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy.
    Shahid M; Spagnolli E; Ernande L; Thoonen R; Kolodziej SA; Leyton PA; Cheng J; Tainsh RE; Mayeur C; Rhee DK; Wu MX; Scherrer-Crosbie M; Buys ES; Zapol WM; Bloch KD; Bloch DB
    Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H984-94. PubMed ID: 26873969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure.
    Beak JY; Kang HS; Huang W; Myers PH; Bowles DE; Jetten AM; Jensen BC
    Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H186-H200. PubMed ID: 30387679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling.
    Izumiya Y; Kim S; Izumi Y; Yoshida K; Yoshiyama M; Matsuzawa A; Ichijo H; Iwao H
    Circ Res; 2003 Oct; 93(9):874-83. PubMed ID: 14551246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-(1-7) attenuates angiotensin II-induced cardiac hypertrophy via a Sirt3-dependent mechanism.
    Guo L; Yin A; Zhang Q; Zhong T; O'Rourke ST; Sun C
    Am J Physiol Heart Circ Physiol; 2017 May; 312(5):H980-H991. PubMed ID: 28411231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSF1 phosphorylation by ERK/GSK3 suppresses RNF126 to sustain IGF-IIR expression for hypertension-induced cardiomyocyte hypertrophy.
    Huang CY; Lee FL; Peng SF; Lin KH; Chen RJ; Ho TJ; Tsai FJ; Padma VV; Kuo WW; Huang CY
    J Cell Physiol; 2018 Feb; 233(2):979-989. PubMed ID: 28383811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium butyrate attenuates angiotensin II-induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6-dependent mechanism.
    Zhang L; Deng M; Lu A; Chen Y; Chen Y; Wu C; Tan Z; Boini KM; Yang T; Zhu Q; Wang L
    J Cell Mol Med; 2019 Dec; 23(12):8139-8150. PubMed ID: 31565858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mep1a contributes to Ang II-induced cardiac remodeling by promoting cardiac hypertrophy, fibrosis and inflammation.
    Ge W; Hou C; Zhang W; Guo X; Gao P; Song X; Gao R; Liu Y; Guo W; Li B; Zhao H; Wang J
    J Mol Cell Cardiol; 2021 Mar; 152():52-68. PubMed ID: 33301800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.